Infliximab for Ulcerative Colitis

[1]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[2]  J. Gisbert,et al.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial , 2012, The Lancet.

[3]  M. Färkkilä,et al.  Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF&agr; blocking agents , 2012, Inflammatory bowel diseases.

[4]  O. Dewit,et al.  Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. , 2012, Journal of Crohn's & colitis.

[5]  Rasmus Goll,et al.  Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis , 2012, Scandinavian journal of gastroenterology.

[6]  G. D'Haens,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[7]  P. Rutgeerts,et al.  Long‐term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT‐1 and ‐2 Extension Studies , 2012, Inflammatory bowel diseases.

[8]  P. Hellström,et al.  Infliximab or Cyclosporine as Rescue Therapy in Hospitalized Patients with Steroid‐Refractory Ulcerative Colitis: A Retrospective Observational Study , 2012, Inflammatory bowel diseases.

[9]  J. Gisbert,et al.  Infliximab salvage therapy after failure of ciclosporin in corticosteroid‐refractory ulcerative colitis: a multicentre study , 2012, Alimentary pharmacology & therapeutics.

[10]  R. Porcher,et al.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. , 2012, Gastroenterology.

[11]  P. Rutgeerts,et al.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.

[12]  O. Dewit,et al.  Successive Treatment With Cyclosporine and Infliximab in Steroid-Refractory Ulcerative Colitis , 2011, The American Journal of Gastroenterology.

[13]  L. A. Christensen,et al.  Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. , 2011, Journal of Crohn's & colitis.

[14]  B. Flourié,et al.  A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization , 2010, The American Journal of Gastroenterology.

[15]  J. Brynskov,et al.  Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: A Danish single center experience , 2010, Scandinavian journal of gastroenterology.

[16]  P. Rutgeerts,et al.  Management of acute severe ulcerative colitis , 2010, Gut.

[17]  P. Hellström,et al.  Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study , 2010, Alimentary pharmacology & therapeutics.

[18]  S. Brand,et al.  Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis , 2010, The American Journal of Gastroenterology.

[19]  P. Rutgeerts,et al.  Predicting the response to infliximab from trough serum levels , 2009, Gut.

[20]  S. Hanauer,et al.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. , 2009, Gastroenterology.

[21]  G Van Assche,et al.  Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.

[22]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[23]  P. Rutgeerts,et al.  751f One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy , 2009 .

[24]  G. Cui,et al.  TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. , 2009, Cytokine.

[25]  P. Rutgeerts,et al.  P087 - SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy , 2008 .

[26]  K. Van Steen,et al.  Long-term outcome after infliximab for refractory ulcerative colitis. , 2008, Journal of Crohn's & colitis.

[27]  J. Mate,et al.  Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. , 2007, Hepato-gastroenterology.

[28]  A. Gasbarrini,et al.  Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up , 2007, Alimentary pharmacology & therapeutics.

[29]  C. Lees,et al.  A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[30]  F. Klebl,et al.  Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients , 2007, Inflammatory bowel diseases.

[31]  S. Travis,et al.  Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006 , 2007, Alimentary pharmacology & therapeutics.

[32]  P. Rutgeerts,et al.  The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients , 2007, The American Journal of Gastroenterology.

[33]  Konstantinos H. Katsanos,et al.  Predictors of early response to infliximab in patients with ulcerative colitis , 2007, Inflammatory bowel diseases.

[34]  P. Rutgeerts,et al.  Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[35]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[36]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[37]  D. Jewell,et al.  Ciclosporin use in acute ulcerative colitis: a long-term experience , 2005, European journal of gastroenterology & hepatology.

[38]  B. Göke,et al.  Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study , 2004, European journal of gastroenterology & hepatology.

[39]  A. Gasbarrini,et al.  Infliximab in the treatment of steroid-dependent ulcerative colitis. , 2004, European review for medical and pharmacological sciences.

[40]  Tatsuo Tanaka,et al.  Correlation of Serum Soluble TNF-α Receptors I and II Levels with Disease Activity in Patients with Ulcerative Colitis , 2004, American Journal of Gastroenterology.

[41]  S. Hanauer.  Medical therapy for ulcerative colitis 2004. , 2004, Gastroenterology.

[42]  R. Modigliani,et al.  Infliximab for refractory ulcerative colitis or indeterminate colitis: an open‐label multicentre study , 2003, Alimentary pharmacology & therapeutics.

[43]  A. Forbes,et al.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial , 2003, Gut.

[44]  B. Iizuka,et al.  Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis , 2002, American Journal of Gastroenterology.

[45]  J. Lewis,et al.  Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. , 2002 .

[46]  P. Rutgeerts.  Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trials. , 2002 .

[47]  G. Actis,et al.  Infliximab for treatment of steroid-refractory ulcerative colitis. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[48]  H. Tilg,et al.  Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. , 2001, Wiener klinische Wochenschrift.

[49]  W. Chey,et al.  Infliximab for refractory ulcerative colitis. , 2001 .

[50]  S. Targan,et al.  Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study , 2001, Inflammatory bowel diseases.

[51]  S. Hanauer.  Medical therapy for ulcerative colitis. , 2000, Current opinion in gastroenterology.

[52]  B. Vainer,et al.  Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-α in ulcerative colitis , 1999, American Journal of Gastroenterology.

[53]  L. Chauvelot‐Moachon,et al.  Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis , 1998, American Journal of Gastroenterology.

[54]  S. Stephens,et al.  Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. , 1997, Gut.

[55]  F. Hadžiselimović,et al.  Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. , 1995, Gut.

[56]  P. Munkholm,et al.  Course of ulcerative colitis: analysis of changes in disease activity over years. , 1994, Gastroenterology.

[57]  S. Hanauer,et al.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.

[58]  T. Macdonald,et al.  Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. , 1993, Gut.

[59]  S. Stephens,et al.  Tumour necrosis factor alpha in stool as a marker of intestinal inflammation , 1992, The Lancet.

[60]  A. Cooke,et al.  Tumour necrosis factor‐alpha and interferon‐gamma production measured at the single cell level in normal and inflamed human intestine , 1990, Clinical and experimental immunology.

[61]  G. Järnerot,et al.  Intensive intravenous treatment of ulcerative colitis. , 1985, Gastroenterology.

[62]  A. W. Woodruff,et al.  A case of rabies in man: some problems in diagnosis and management. , 1976, British medical journal.

[63]  D. Jewell,et al.  Intensive intravenous regimen for severe attacks of ulcerative colitis. , 1974, Lancet.

[64]  S. Truelove,et al.  The course and prognosis of ulcerative colitis , 1963, Gut.

[65]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .